Compare Innodata Inc (INOD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs GeneDx Holdings Corp — how do they compare? Innodata Inc trades at $62 (market cap $2.10B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Innodata Inc and GeneDx Holdings Corp are close in size by market cap, and Innodata Inc is more actively traded (989,493 versus 734,640). Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and GeneDx Holdings Corp for 19 Days on average.
| INOD | WGS | |
|---|---|---|
Market Cap | $2.10B | $2.02B |
Volume | 989,493 | 734,640 |
Sector | Technology | Health |
52-Week High | $121.50 | $167.51 |
52-Week Low | $34.45 | $34.51 |
Typical Hold Time | 19 Days | 19 Days |
Enterprise Value | $1.86B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $61.54, down 2.96% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consecutive earnings beats, with Q1 2026 EPS of $0.42 significantly exceeding the $0.13 estimate, and demonstrated robust revenue growth from $252M in 2025 to $317M projected for 2026. Analyst sentiment remains positive with a 67% buy rating, though the stock faces valuation concerns with a P/E of 47.4.
The outlook for INOD is mixed: strong AI-driven revenue growth and expanding margins support upside potential, but high valuation multiples and bearish technical signals present near-term risks. Investor focus should remain on execution of new initiatives like the motion-capture AI lab and customer diversification efforts to justify premium pricing.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
